COMP <GO>
RXRX vs UNH // ENTERPRISE SCALE & MARKET CAP
Recursion Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: RXRX 2
— UNH 11
▲ ENTERPRISE SCALE & MARKET CAP LEADER: UNH
LAST: $3.83 (-4.96%) • MKT CAP: $2.29B
market-cap
$2.29B
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
market-cap
$359.43B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RXRX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RXRX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 5.00% | 88.31% | -83.31 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 12.38% | -47.38 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -14.95% | 6.25% | -21.20 | UNH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 5.32% | -65.32 | UNH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 3.53% | -63.53 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 26.90% | 3.33% | +23.57 | RXRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.59 | 3.09 | -1.50 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.8 | 55.1 | -7.30 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.33 | +0.67 | RXRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 17.7x | +14.26 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.29B | $359.43B | -$357.15B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RXRX REV | UNH REV | RXRX GROSS % | UNH GROSS % | RXRX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $74.7M | $447.57B | 5.0% | 88.7% | -$378.3M | $16.07B |
| FY 2024 | $58.8M | $400.28B | 23.1% | 88.3% | -$372.9M | $20.70B |
| FY 2023 | $44.6M | $371.62B | — | 89.6% | -$289.8M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RXRX // BETA 1.00
UNH // BETA 0.33